Do hormone treatments cause anxiety and depression among prostate cancer patients?

David Christie, Christopher Sharpley, Vicki Bitsika

Research output: Contribution to journalMeeting AbstractResearchpeer-review

Abstract

Objective
To investigate the relationship between Hormone Therapy (HT) and incidence on anxiety and depression in prostate cancer patients (PCa).

Methods
526 PCa patients completed a survey about their cancer status, treatments received, anxiety and depression status. Total scores on anxiety and depression inventories, plus symptom profiles that discriminated between patients with current HT, past HT, and never having received HT, were compiled for analysis.

Results
Patients who were currently receiving HT had significantly higher total anxiety and depression scores than patients who had previously received HT or who had never received HT. Analysis of the symptoms of anxiety and depression which distinguished between these groups of patients suggested that patients who had never received HT had significantly lower scores than current or past HT patients. Although several symptoms could be directly allocated to PCa and/or HT, symptom profiles were indicative of clinically significant anxiety and/or depression in patients who were currently receiving, or who had previously received, HT

Conclusion
Current HT may lead to symptoms of anxiety and/or depression which require clinical attention. These effects appear to decrease after completion of HT.
Original languageEnglish
Pages (from-to)56-57
Number of pages2
JournalBJU International
Volume112
DOIs
Publication statusPublished - Aug 2013

Cite this

Christie, David ; Sharpley, Christopher ; Bitsika, Vicki. / Do hormone treatments cause anxiety and depression among prostate cancer patients?. In: BJU International. 2013 ; Vol. 112. pp. 56-57.
@article{432a85fbbdd14ebb967c26db65097358,
title = "Do hormone treatments cause anxiety and depression among prostate cancer patients?",
abstract = "ObjectiveTo investigate the relationship between Hormone Therapy (HT) and incidence on anxiety and depression in prostate cancer patients (PCa).Methods526 PCa patients completed a survey about their cancer status, treatments received, anxiety and depression status. Total scores on anxiety and depression inventories, plus symptom profiles that discriminated between patients with current HT, past HT, and never having received HT, were compiled for analysis.ResultsPatients who were currently receiving HT had significantly higher total anxiety and depression scores than patients who had previously received HT or who had never received HT. Analysis of the symptoms of anxiety and depression which distinguished between these groups of patients suggested that patients who had never received HT had significantly lower scores than current or past HT patients. Although several symptoms could be directly allocated to PCa and/or HT, symptom profiles were indicative of clinically significant anxiety and/or depression in patients who were currently receiving, or who had previously received, HTConclusionCurrent HT may lead to symptoms of anxiety and/or depression which require clinical attention. These effects appear to decrease after completion of HT.",
author = "David Christie and Christopher Sharpley and Vicki Bitsika",
year = "2013",
month = "8",
doi = "10.1111/bju.12294",
language = "English",
volume = "112",
pages = "56--57",
journal = "British Journal of Urology",
issn = "1464-410X",
publisher = "Wiley-Blackwell",

}

Do hormone treatments cause anxiety and depression among prostate cancer patients? / Christie, David; Sharpley, Christopher; Bitsika, Vicki.

In: BJU International, Vol. 112, 08.2013, p. 56-57.

Research output: Contribution to journalMeeting AbstractResearchpeer-review

TY - JOUR

T1 - Do hormone treatments cause anxiety and depression among prostate cancer patients?

AU - Christie, David

AU - Sharpley, Christopher

AU - Bitsika, Vicki

PY - 2013/8

Y1 - 2013/8

N2 - ObjectiveTo investigate the relationship between Hormone Therapy (HT) and incidence on anxiety and depression in prostate cancer patients (PCa).Methods526 PCa patients completed a survey about their cancer status, treatments received, anxiety and depression status. Total scores on anxiety and depression inventories, plus symptom profiles that discriminated between patients with current HT, past HT, and never having received HT, were compiled for analysis.ResultsPatients who were currently receiving HT had significantly higher total anxiety and depression scores than patients who had previously received HT or who had never received HT. Analysis of the symptoms of anxiety and depression which distinguished between these groups of patients suggested that patients who had never received HT had significantly lower scores than current or past HT patients. Although several symptoms could be directly allocated to PCa and/or HT, symptom profiles were indicative of clinically significant anxiety and/or depression in patients who were currently receiving, or who had previously received, HTConclusionCurrent HT may lead to symptoms of anxiety and/or depression which require clinical attention. These effects appear to decrease after completion of HT.

AB - ObjectiveTo investigate the relationship between Hormone Therapy (HT) and incidence on anxiety and depression in prostate cancer patients (PCa).Methods526 PCa patients completed a survey about their cancer status, treatments received, anxiety and depression status. Total scores on anxiety and depression inventories, plus symptom profiles that discriminated between patients with current HT, past HT, and never having received HT, were compiled for analysis.ResultsPatients who were currently receiving HT had significantly higher total anxiety and depression scores than patients who had previously received HT or who had never received HT. Analysis of the symptoms of anxiety and depression which distinguished between these groups of patients suggested that patients who had never received HT had significantly lower scores than current or past HT patients. Although several symptoms could be directly allocated to PCa and/or HT, symptom profiles were indicative of clinically significant anxiety and/or depression in patients who were currently receiving, or who had previously received, HTConclusionCurrent HT may lead to symptoms of anxiety and/or depression which require clinical attention. These effects appear to decrease after completion of HT.

U2 - 10.1111/bju.12294

DO - 10.1111/bju.12294

M3 - Meeting Abstract

VL - 112

SP - 56

EP - 57

JO - British Journal of Urology

JF - British Journal of Urology

SN - 1464-410X

ER -